PepGen Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de PepGen disminuyan a un ritmo anual de 1.8%, mientras que sus ingresos anuales crecerán a un ritmo de 77.7% por año. Se espera que el BPA crezca en un 9% al año.

Información clave

-1.8%

Tasa de crecimiento de los beneficios

9.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.5%
Tasa de crecimiento de los ingresos	77.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	18 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

Nov 19

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Aug 06

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

Jul 31

Here's Why We're Not Too Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

Sep 07

PepGen GAAP EPS of -$1.23 misses by $0.47

Aug 12

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:PEPG - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-113	-129	-147	3
12/31/2025	N/A	-113	-116	-125	4
12/31/2024	N/A	-95	-95	-89	4
9/30/2024	N/A	-87	-83	-82	N/A
6/30/2024	N/A	-89	-75	-75	N/A
3/31/2024	N/A	-80	-78	-76	N/A
12/31/2023	N/A	-79	-72	-69	N/A
9/30/2023	N/A	-74	-66	-63	N/A
6/30/2023	N/A	-69	-71	-67	N/A
3/31/2023	N/A	-67	-66	-62	N/A
12/31/2022	N/A	-69	-63	-59	N/A
9/30/2022	N/A	-61	-55	-52	N/A
6/30/2022	N/A	-51	-41	-39	N/A
3/31/2022	N/A	-39	-34	-32	N/A
12/31/2021	N/A	-27	-23	-23	N/A
9/30/2021	N/A	-23	-17	-17	N/A
6/30/2021	N/A	-15	-10	-10	N/A
3/31/2021	N/A	-10	-4	-4	N/A
12/31/2020	N/A	-4	-2	-2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que PEPG siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que PEPG siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que PEPG siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que PEPG no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que PEPG no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PEPG se prevé que sea elevada dentro de 3 años.

PepGen Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 13% to US$17.00

Price target decreased by 9.3% to US$19.60

Price target decreased by 14% to US$20.00

Recent updates

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

Price target decreased by 13% to US$17.00

New major risk - Revenue and earnings growth

PepGen Inc. Announces Christopher Ashton to Retire from Its Board of Directors, Effective September 30, 2024

New major risk - Share price stability

PepGen Inc. Appoints Paul Streck as Executive Vice President, Head of Research & Development, Head of Research & Development

Price target decreased by 9.3% to US$19.60

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Chief Medical Officer exercised options and sold US$61k worth of stock

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

PepGen Inc. Announces Positive Data from Low-Dose Cohort of Pgn-Edo51 in Ongoing Connect1-Edo51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

Chief Medical Officer exercised options and sold US$72k worth of stock

PepGen Inc. Appoints Afsaneh Mohebbi as SVP, Portfolio and Program Management and Dave Borah as SVP, Investor Relations and Corporate Communications

Chief Medical Officer exercised options and sold US$74k worth of stock

Pepgen Inc. Announces Executive Promotions

Insider notifies of intention to sell stock

The Prognosis For PepGen

Senior Vice President of Chemistry notifies of intention to sell stock

PepGen Inc., Annual General Meeting, Jun 20, 2024

PepGen Inc., Annual General Meeting, Jun 20, 2024

PepGen Inc. Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Inc. Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1

PepGen Inc. has completed a Follow-on Equity Offering in the amount of $80.08155 million.

New minor risk - Shareholder dilution

New major risk - Share price stability

Price target decreased by 14% to US$20.00

PepGen: Long Road Ahead

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

Pepgen Inc. Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of P GN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

Pepgen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

Pepgen Announces First Patient Dosed in Phase 1 Freedom-Dm1 Clinical Trial of Pgn-Edodm1 for Myotonic Dystrophy Type 1

PepGen Inc. Announces Appointment of Howard Mayer, M.D. to Board of Directors

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

New major risk - Revenue and earnings growth

PepGen Inc. Announces FDA Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDO Program at Two Medical Conferences

New major risk - Share price stability

New major risk - Revenue and earnings growth

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1

New major risk - Share price stability

Pepgen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate A Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1

PepGen Inc. to Report Q1, 2023 Results on May 11, 2023

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Key Executive notifies of intention to sell stock

We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth

PepGen Inc. Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies

High number of new and inexperienced directors

PepGen Inc. Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates

PepGen Inc. Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Appoints Habib Dable to Board of Directors

Here's Why We're Not Too Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

PepGen GAAP EPS of -$1.23 misses by $0.47

PepGen Inc. Appoints Caroline Godfrey to Its Scientific Advisory Board

PepGen Inc. has completed an IPO in the amount of $108 million.

High number of new and inexperienced directors

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento